Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Bhuvaneswari Ramaswamy
- Target Recruit Count
- 6
- Registration Number
- NCT00824733
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00821886
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Medical Oncology Associates of Augusta, Augusta, Georgia, United States
🇺🇸Mercy Hospital, Portland, Maine, United States
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2019-04-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 540
- Registration Number
- NCT00820222
- Locations
- 🇬🇧
Novartis Investigative Site, Worthing, United Kingdom
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2012-12-11
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00817362
- Locations
- 🇺🇸
Boca Raton Comphrensive Cancer Care, Boca Raton, Florida, United States
🇺🇸Medical College of Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States
Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Medstar Health Research Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00810017
- Locations
- 🇺🇸
Washington Cancer Institute, Washington, District of Columbia, United States
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2011-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 29
- Registration Number
- NCT00803556
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States
Chemotherapeutic Agents in Brain/Breast
- Conditions
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT00795678
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT00788931
- Locations
- 🇳🇱
Novartis Investigative Site, Amsterdam, Netherlands
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
- Conditions
- Interventions
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 720
- Registration Number
- NCT00781612
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States
🇺🇸Comp Cancer Centers of Nevada, Los Angeles, California, United States
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 305
- Registration Number
- NCT00770809
- Locations
- 🇺🇸
Greene Memorial Hospital, Xenia, Ohio, United States
🇺🇸Boulder Community Hospital, Boulder, Colorado, United States
🇺🇸Atrium Health Navicent, Macon, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.